Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Roger's 1998 Short Picks -- Ignore unavailable to you. Want to Upgrade?

To: Wowzer who wrote (8857)	5/16/1998 2:24:00 PM
From: BDR	Read Replies (1) \| Respond to of 18691

To the thread, re:HEPH- I hadn't been following this one lately but came across this release about a convertible: (excerpt) SAN DIEGO, May 8 /PRNewswire/ -- Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: HEPH), a biopharmaceutical company engaged in the development and commercialization of products for the treatment of infectious diseases and immune system disorders, today announced that it has closed a private financing of approximately $17 million. An aggregate of 1,007,538 Common Shares, $4 million principal amount of Convertible Preferred Stock, and Warrants to purchase 963,808 shares of Common Stock at $17.00 per share were issued in the financing. The Convertible Preferred Stock has an initial conversion price of $20.30 for the first seven months, after which it can be adjusted, either up or down, based on the future stock prices of the Company's Common Stock. The financing involved institutional investors and existing stockholders including Colthurst Ltd.. Colthurst Ltd. is controlled by Patrick T. Prendergast Ph.D., founding scientist of the Company. Hollis-Eden and its research affiliates now have approximately $25 million in cash and cash equivalents. The Company has 7,835,708 shares of Common Stock outstanding. .......... Floorless after seven months? Diluting outside investors interests in favor of Prendergast?